Acumen Pharmaceuticals (ABOS) Total Liabilities (2020 - 2026)

Acumen Pharmaceuticals' Total Liabilities history runs 7 years deep, the most recent figure standing at $46.2 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 5.73% year-over-year to $46.2 million; the TTM figure through Mar 2026 stood at $46.2 million (down 5.73% YoY), while the FY2025 annual figure was $52.4 million, down 8.35% from the prior year.
• Total Liabilities came in at $46.2 million for Q1 2026 at Acumen Pharmaceuticals, down from $52.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $57.2 million in Q4 2024 to a low of $4.0 million in Q1 2022.
• A 5-year average of $31.3 million and a median of $43.2 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities tumbled 91.21% in 2022 and jumped 716.22% in 2024, its largest moves.
• Acumen Pharmaceuticals' Total Liabilities stood at $7.8 million in 2022, then surged by 452.38% to $43.2 million in 2023, then surged by 32.5% to $57.2 million in 2024, then declined by 8.35% to $52.4 million in 2025, then declined by 11.93% to $46.2 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $46.2 million, $52.4 million, and $49.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison